Cardiovascular disease is highly prevalent among HIV-infected patients, however the distinct mechanisms of atherosclerotic disease development in HIV-infected patients are yet unknown. Chronic HIV infection is associated with loss of gastrointestinal mucosal epithelial integrity and loss of CD4+ T-cells in the intestinal lamina propria, leading to increased microbial translocation across the gastrointestinal tract. The key hypothesis of this grant application is that microbial translocation causes activation of the innate immune system which can induce inflammatory damage in the vasculature, leading to cardiovascular disease. This application proposes to investigate the role of the intestinal mucosal barrier to innate immune activation and downstream effects on atherosclerotic disease in HIV-infected patients.
Aim 1 seeks to study the relationships of intestinal epithelial integrity and microbial translocation to monocyte and macrophage activation and to cardiovascular risk measured by arterial inflammation via FDG-PET (to assess arterial macrophage activity) and coronary cardiac computed tomography angiography (to assess coronary atherosclerotic plaque quantitatively and qualitatively). Transcriptomic analyses in monocytes are proposed to identify novel biological pathways of atherogenesis in HIV-infected patients. To further test the central hypothesis, an interventional study is proposed in Aim 2 to improve the gut epithelial integrity and reduce microbial translocation in order to test effects of such an intervention on cardiovascular inflammation and monocyte function. The intervention of teduglutide, a glucagon-like peptide 2 analog with known trophic and anti-inflammatory effects on the intestinal epithelium, will be investigated in a randomized, double-blind placebo-controlled proof of concept trial in HIV-infected individuals. The hypothesis to be tested is that improvement of gut epithelial integrity will decrease intestinal permeability to microbial products, thus decreasing the stimulus for monocyte and macrophage activation, and therefore decrease macrophage activity in the arterial wall measured by FDG-PET and reduce overall cardiovascular risk.
Cardiovascular disease is an emerging problem among patients living with HIV infection. As HIV-infected patients can have increased intestinal damage leading to excess bacterial products crossing over the intestinal mucosal barrier, which we hypothesize can lead to increased inflammation and thus atherosclerosis. In this grant application, we will examine whether abnormalities in the intestinal mucosal barrier can affect inflammation downstream in the blood vessels of the heart. We will also perform a randomized double-blind placebo-controlled trial to study whether treatment to improve the integrity of the mucosal barrier can help to decrease inflammation in the blood vessels of the heart and thus affect the development of atherosclerosis.
|Cheru, Lediya T; Fitch, Kathleen V; Saylor, Charles F et al. (2018) Mild renal impairment is associated with calcified plaque parameters assessed by CT angiography in people living with HIV. AIDS :|
|Cheru, Lediya T; Park, Elli A; Saylor, Charles F et al. (2018) I-FABP Is Higher in People With Chronic HIV Than Elite Controllers, Related to Sugar and Fatty Acid Intake and Inversely Related to Body Fat in People With HIV. Open Forum Infect Dis 5:ofy288|
|deFilippi, Christopher; Christenson, Robert; Joyce, Jessica et al. (2018) Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV. J Acquir Immune Defic Syndr 78:105-110|
|Nou, Eric; Lo, Janet; Grinspoon, Steven K (2016) Inflammation, immune activation, and cardiovascular disease in HIV. AIDS 30:1495-509|